TSSC3 (PHLDA2) (NM_003311) Human Recombinant Protein

CAT#: TP720902L

Purified recombinant protein of Human pleckstrin homology-like domain, family A, member 2 (PHLDA2)

Size: 10 ug 50 ug 500 ug 1 mg



Need it in bulk or customized?
Get a free quote

CNY 18,030.00


货期*
2周

规格
    • 500 ug

Product images

经常一起买 (1)
Rabbit Polyclonal Anti-PHLDA2 Antibody - middle region
    • 100 ul

CNY 5,250.00

Specifications

Product Data
Species Human
Expression Host E. coli
Expression cDNA Clone or AA Sequence
Tag C-His
Predicted MW 18.1 kDa
Concentration lot specific
Purity >95% as determined by SDS-PAGE and Coomassie blue staining
Buffer Lyophilized from a 0.2 um filtered solution of 20mMTris-HCl,350mMNaCl,1mM DTT,pH8.0.
Storage Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Stability Stable for at least 6 months from date of receipt under proper storage and handling conditions.
Endotoxin Endotoxin level is < 0.1 ng/µg of protein (< 1 EU/µg)
Reference Data
RefSeq NP_003302
Locus ID 7262
UniProt ID Q53GA4
Refseq Size 937
Cytogenetics 11p15.4
Refseq ORF 456
Synonyms BRW1C; BWR1C; HLDA2; IPL; TSSC3
Summary This gene is located in a cluster of imprinted genes on chromosome 11p15.5, which is considered to be an important tumor suppressor gene region. Alterations in this region may be associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene has been shown to be imprinted, with preferential expression from the maternal allele in placenta and liver. [provided by RefSeq, Oct 2010]
Protein Families Druggable Genome
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Customer Reviews 
Loading...